Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.66 |
| ▸ | ACE | P12821 | 4/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011726 | 1.00 | MME (0.66) | MMEACEENPEPOPRD1 | |
| SCHEMBL30011828 | 1.00 | MME (0.66) | MMEACEENPEPOPRD1 | |
| SCHEMBL30011159 | 1.00 | MME (0.66) | MMEACEENPEPOPRD1 | |
| SCHEMBL30010977 | 1.00 | MME (0.66) | MMEACEENPEPOPRD1 | |
| SCHEMBL30011801 | 1.00 | MME (0.66) | MMEACEENPEPOPRD1 | |
| SCHEMBL29938305 | 0.96 | MME (0.71) | MMEACE | |
| SCHEMBL30011732 | 0.96 | MME (0.71) | MMEACE | |
| SCHEMBL29938283 | 0.96 | MME (0.71) | MMEACE | |
| SCHEMBL30010229 | 0.96 | MME (0.71) | MMEACE | |
| SCHEMBL30010408 | 0.96 | MME (0.60) | MMEACEENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | MME 1902/4885ACE 4699/4885ENPEP 1575/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | MME 2664/4885ACE 4227/4885ENPEP 910/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | MME 1902/4885ACE 4699/4885ENPEP 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.